
Genovis Q3 2023 - Solid growth and profitability, Xork timeline remains on track

Redeye updates its view on Genovis following its Q3 2023 report and the announced merger between Selecta and Cartesian Therapeutics. We continue to see an exciting and compelling growth case, which should offer an attractive opportunity in the share in 2024.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Genovis Q3 2023 - Solid growth and profitability, Xork timeline remains on track](#)